• 1
    Glicklich R, Dreyer N. Registries for Evaluating Patient Outcomes: A User's Guide, 2nd edition, Agency for Healthcare Research and Quality (US), Rockville (MD), 2010.
  • 2
    Müller D, Augustin M, Banik N et al. [Memorandum registry for health services research]. Gesundheitswesen 2010; 72: 82439.
  • 3
    Rustenbach SJ, Heyer K, Reppenhagen K, Augustin M. Registerforschung in der Dermatologie. Der Hautarzt 2011; 11: 18995.
  • 4
    Zink A, Strangfeld A, Schneider M, Herzer P et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006; 54: 3399407.
  • 5
    Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 4155.
  • 6
    The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology [Internet]. cited: 2013 October 31. Available from:
  • 7
    Administration USDoHaHSFFaD. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79.
  • 8
    Agency EM. Not for Guidance on Clinical Safety Data Management. 2006.
  • 9
    Agency EM. Volume 9A of The Rules Governing Medicinal Products in the European Union – Guidelines on Pharmacovigilance for Medicinal Products for Human Use. 2008.
  • 10
    European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. European Medicines Agency, 2012.
  • 11
    Augustin M, Alvaro-Gracia JM, Bagot M et al. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol 2012; 26(Suppl 4): 116.
  • 12
    Luger T, Reusch M, Reich K et al. Stellungnahme der DDG und des BVDD zur EMEA-Empfehlung über das Ruhen der Zulassung für Raptiva® (Efalizumab). J Dtsch Dermatol Ges 2009; 7: 2912.
  • 13
    Zink A, Listing J, Klindworth C, Zeidler H. The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann Rheum Dis 2001; 60: 199206.
  • 14
    Ormerod AD, Augustin M, Baker C et al. Challenges for synthesising data in a network of registries for systemic psoriasis therapies. Dermatology 2012; 224: 23643.
  • 15
    PsoNet. PsoNet. European Registry of Psoriasis. Centro Studi GISED. [Internet]. cited: 2013 October 31. Available from:
  • 16
    Schmitt-Egenolf M. Psoriasis therapy in real life: the need for registries. Dermatology 2006; 213: 32730.
  • 17
    Nast A, Boehncke W, Mrowietz U et al. German S3-guidelines on the treatment of psoriasis vulgaris update 2011. J Dtsch Dermatol Ges 2012; 9: S1S104.
  • 18
    Mrowietz U, Kragballe K, Reich K et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303(1): 110.
  • 19
    Lecluse LL, Naldi L, Stern RS et al. National registries of systemic treatment for psoriasis and the European ‘Psonet’ initiative. Dermatology 2009; 218(4): 34756.
  • 20
    Medical Dictionary for Regulatory Activities terminology is the international medical terminology developed under the auspices of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Los Angeles: MedDRA® trademark is owned by IFPMA on behalf of ICH.
  • 21
    (ISPE) ISoP. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2008; 17: 2008.
  • 22
    (DAE) AEMdDAfE. Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP) 2004.
  • 23
    PsoBest. Das deutsche Psoriasis-Register. [Internet]. cited: 2013 October 31. Available from:
  • 24
    von Elm E, Altman DG, Egger M et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335: 8068.
  • 25
    Augustin M, Reich K, Reich C et al. Quality of Psoriasis Care in Germany – Results of the National Study PsoHealth 2007. J Dtsch Dermatol Ges 2008; 6: 6406.
  • 26
    Franzke N, Montenbruck M, Langenbruch A et al. Drug supply for psoriasis – results from a national pharmacy network. J Dtsch Dermatol Ges 2013; 11: 63843.
  • 27
    Langenbruch A, Schaefer I, Franzke N, Augustin M. Internet-supported gathering of treatment data and patient benefits in psoriasis. J Eur Acad Dermatol Venereol 2010; 24: 5417.
  • 28
    Langenbruch A, Radtke MA, Augustin M. Quality of psoriasis care from the patients’ perspective – Results of the national health care study PsoReal. Eur J Dermatol 2012; 22: 51824.
  • 29
    Augustin M, Krueger K, Radtke MA et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter prospective cross-sectional study in Germany. Dermatology 2008; 216: 36672.
  • 30
    Papp KA, Strober B, Augustin M et al. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol 2012; 11: 12107.